The Phase I study of Decitabine in combination with Valproic Acid is sponsored by the National Cancer Institute and focuses on patients with refractory or relapsed acute myeloid leukemia (AML) and previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The combination therapy aims to improve treatment outcomes by leveraging the distinct mechanisms of action of both agents. Given the high unmet medical need in these patient populations, successful outcomes could position this combination as a competitive option in the oncology market. The results may also provide insights into the broader application of epigenetic therapies in hematologic cancers, potentially attracting interest from pharmaceutical companies looking to expand their oncology portfolios.